Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Aptose Biosciences Inc    APS   CA03835T2002

APTOSE BIOSCIENCES INC (APS)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
09/13/2018 09/14/2018 09/17/2018 09/18/2018 09/19/2018 Date
3.58(c) 3.55(c) 3.47(c) 3.36(c) 3.43 Last
57 576 26 318 26 837 34 757 4 900 Volume
-4.28% -0.84% -2.25% -3.17% +2.08% Change
More quotes
Financials (CAD)
Sales 2018 -
EBIT 2018 -39,3 M
Net income 2018 -28,9 M
Debt 2018 -
Yield 2018 -
Sales 2019 0,01 M
EBIT 2019 -42,7 M
Net income 2019 -28,8 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 12 778x
Capitalization 115 M
More Financials
Company
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies.Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG'806 a non-covalent small... 
More about the company
Latest news on APTOSE BIOSCIENCES INC
09/10Today's Research Reports on Aralez Pharmaceuticals, OrganiGram Holdings, Onco..
AC
08/29Aptose to Present at Upcoming Investor Conferences in September 2018
GL
08/15Aptose Announces Appointment of Carol Ashe to Board of Directors
GL
08/10Today's Research Reports on Emblem, OrganiGram Holdings, Oncolytics Biotech a..
AC
08/07Aptose Reports Results for the Second Quarter Ended June 30, 2018
GL
08/02Aptose Biosciences to Present at Canaccord Genuity 38th Annual Growth Confere..
GL
07/24Aptose To Release Second Quarter Ended June 30, 2018 Financial Results and Ho..
GL
07/11Today's Research Reports on Emblem, OrganiGram, Oncolytics Biotech and Aptose..
AC
07/10Aptose Biosciences and CrystalGenomics Announce Issuance of Japanese Patent f..
GL
07/09Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncolo..
GL
More news
Sector news : Biotechnology & Medical Research - NEC
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans -- U..
DJ
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/12EUROPE : European stocks shrug off trade worries as oil stocks rally
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
08/14Aptose Biosciences $APTO Lifted to Hold at Zacks Investment Research  
08/10Financial Survey: bluebird bio $BLUE and Aptose Biosciences $APTO  
08/09Aptose Biosciences $APTO Announces Earnings Results  
08/07Aptose Biosciences misses by $0.15  
08/07Aptose Biosciences $APTO to Release Earnings on Tuesday  
More tweets
Qtime:18
News from SeekingAlpha
09/05Aptose Biosciences (APTO) Presents At Rodman & Renshaw.C. Wainwright 20th Ann.. 
08/09Aptose Now In 'Hurry Up And Wait' Mode 
08/07Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2018 Results - Earnings.. 
08/07Aptose Biosciences misses by $0.15 
07/02Aptose Biosciences Back On Track In The Clinic 
Chart APTOSE BIOSCIENCES INC
Duration : Period :
Aptose Biosciences Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APTOSE BIOSCIENCES INC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 9,21  CAD
Spread / Average Target 174%
EPS Revisions
Managers
NameTitle
William G. Rice Chairman, President & Chief Executive Officer
Gregory K. Chow Chief Financial Officer & Senior Vice President
Stephen B. Howell Chief Medical Officer
Ernest Kitt Vice President-Development & Technical Operations
Denis R. Burger Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
APTOSE BIOSCIENCES INC20.86%92
CELLTRION, INC.--.--%33 722
IQVIA HOLDINGS INC28.24%25 338
LONZA GROUP20.74%24 487
INCYTE CORPORATION-29.24%14 247
SEATTLE GENETICS, INC.45.25%12 094